Fig. 2: Gilteritinib treatment inhibits cell proliferation and formation in vitro.
From: Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors
A, B KYSE30, A2780, and HGC-27 cells were treated with gilteritinib at different concentrations for 24 h, and then stained using the EdU assay. C, D KYSE30, A2780, and HGC-27 cells were treated with the indicated concentrations of gilteritinib for 7 days, and the resulting cell colonies were fixed and stained with crystal violet and counted. E–G Cell spheroids (KYSE30-s, A2780-s, and HGC-27-s) were treated with different concentration of gilteritinib for 72 h. E Morphological alterations in KYSE30-s, A2780-s, and HGC-27-s cells 72 h after gilteritinib treatment using phase contrast microscopy. F The cell viability of spheroids was monitored using the Cell Titer-Glo® Luminescent Cell Viability Assay. G Fluorescence microscopy images showing the viability of KYSE30-s, A2780-s, and HGC-27-s cells cultured in vitro with FDA (Fluorescein diacetate) stain. Scale bars: 100 µm. Data are presented as the mean ± standard error of the mean (SEM); the statistical significance was determined by unpaired t-test (*p < 0.05; **p < 0.01).
